3-(2-Pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity human 5-HT1B/1D ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 3, 2004, Pages 727-729

  Egle, Ian ^a   MacLean, Neil ^a   Demchyshyn, Lidia ^a   Edwards, Louise ^a   Slassi, Abdelmalik ^a   Tehim, Ashok ^a,b  

^a NPS Pharmaceuticals Inc   (Canada)

^b Memory Pharmaceuticals Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; LIGAND; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG POTENCY; DRUG SYNTHESIS; PROTEIN ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 1642452643     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.11.023     Document Type: Article

References (19)

1. Rasmussen B.K., Jensen R., Schole F., Olsen G.F. J. Clin. Epidemiol. 44:1991;1147.
2. Ferrari M.D., Saxena P.R. Eur. J. Neurol. 2:1995;5.
3. Feniuk W., Humphrey P.P.A. Drug Dev. Res. 26:1992;235.
4. Longmore J., Shaw D., Smith D., Hopkins R., McAllister G., Pickard J.D., Sirinathsinghji D.R.D., Butler A.J., Hill R. Cephalagia. 17:1997;833.
5. Glaxo Wellcome Inc. Physicians' Desk Reference, 55th Ed., Medical Economics Company, Montvale, NJ, USA 2001, 1399-1412.
6. Massen Van Den Brink A., Reekers M., Bax W.A., Ferrari M.D., Saxena P.R. Circulation. 98:1998;25.
7. Diener H.-C., Limmroth V. Exp. Opin. Investig. Drugs. 10:2001;1831.
8. Humphrey P.P.A., Goadsby P.J. Cephalalgia. 14:1994;401.
9. Longmore J., Dowson A.J., Hill R.G. Curr. Opin. CPNS Invest. Drugs. 1:1999;39.
10. Isaac M., Slassi M. Idrugs. 4:2001;189.
11. Slassi A., Isaac M., Arora J. Exp. Opin. Ther. Patents. 11:2001;625.
12. Kamboj, R. IBC's 3rd Annual Conference on Migraine: Novel Drugs and Therapeutic Development. Philadelphia, PA, USA 1999.
13. Egle I., MacLean N., Demchyshyn L., Edwards L., Slassi A., Tehim A. Bioorg. Med. Chem. Lett. 13:2003;3419.
14. Slassi A., Edwards L., O'Brien A., Meng C.Q., Xin T., Seto C., Lee D.K.H., MacLean N., Hynd D., Chen C., Wang H., Kamboj R., Rakhit S. Bioorg. Med. Chem. Lett. 10:2000;1707.
15. Slassi, A.; Arora, J.; Tehim, A. WO Patent 2000004019, 2000.
16. 3) δ 0.55 (s, 6H), 0.91 (s, 9H), 1.48 (s, 9H), 1.78-1.83 (m, 5H), 1.95-2.18 (m, 3H), 2.61 (s, 4H), 2.74 (t, 2H), 2.90 (t, 2H), 3.30 (t, 2H), 4.00 (br s, 2H), 6.98 (s, 1H), 7.28 (d, 1H), 7.42 (d, 1H), 7.70 (s, 1H).
17. 3) δ 1.85 (t, 4H), 2.50 (t, 2H), 2.59 (t, 4H), 2.80 (t, 2H), 2.99 (t, 2H), 3.15 (t, 2H), 3.58 (t, 2H), 6.13 (s, 1H), 7.02 (s, 1H), 7.23-7.31 (m, 2H), 7.62 (s, 2H), 7.97 (br s, 1H).
18. 3) δ 1.81 (s, 4H), 2.62 (s, 4H), 2.75 (s, 2H), 2.83 (t, 2H), 3.04 (t, 2H), 3.85 (t, 2H), 4.30 (s, 2H), 6.09 (s, 1H), 6.76 (s, 1H), 7.01 (s, 1H), 7.28-7.33 (m, 1H), 7.42-7.58 (m, 2H), 7.60-7.69 (m, 2H), 7.76 (d, 1H), 7.82-7.95 (m, 2H), 8.22 (s, 1H).
19. Audinot V., Newman-Tancredi A., Millan M. J. Neuropharmacology. 40:2001;57.